Skip to main content

Table 1 Demographic and clinical characteristics and outcomes of hospitalised patients with pneumococcal disease

From: Epidemiology, vaccine effectiveness, and risk factors for mortality for pneumococcal disease among hospitalised adults in Singapore: a case-control study

Characteristics

Pneumococcal disease (N = 496), N(%)

Age, mean (years) ± SD

69.1 ± 15.4

Age group

  < 65 years

170 (34.3)

 65-74 years

125 (25.2)

 75-84 years

131 (26.4)

  ≥ 85 years

70 (14.1)

Gender = male

325 (65.5)

Ethnicity

 Chinese

359 (72.4)

 Malay

61 (12.3)

 Indian

39 (7.9)

 Others

37 (7.5)

Nursing home residence

4 (0.8)

Vaccination status (received ≥ 14 days prior to admission)

 PCV13

6 (1.2)

 PPSV23

78 (15.7)

 Any pneumococcal vaccination

80 (16.1)

 Influenza vaccination in past 1 yr

75 (15.1)

Co-morbidities

 Charlson’s score, median (IQR)

2 (1–4)

 Charlson’s score > 3

137 (27.6)

 Myocardial infarction/Congestive heart failure

143 (28.8)

 Cerebrovascular disease

66 (13.3)

 Dementia

54 (10.9)

 Chronic pulmonary disease

149 (30.0)

 Liver disease

27 (5.4)

 Diabetes mellitus

147 (29.6)

 Renal disease

93 (18.8)

 Any malignancy

53 (10.7)

 Hemiplegia

18 (3.6)

 Peripheral vascular disease

22 (4.4)

 Peptic ulcer disease

17 (3.4)

 Connective tissue disease

8 (1.6)

 AIDs

3 (0.6)

Primary diagnosis

 Pneumonia

347 (70.0)

 Sepsis

63 (12.7)

 Meningitis

5 (1.0)

 Other respiratory diseases

73 (14.7)

 Other diagnoses

8 (1.6)

Outcomes

 ICU admission

54 (11.0)

 Length of stay (days), median (IQR)

8 (5–14)

 Length of stay > 7 days

275 (55.4)

 In-hospital mortality

70 (14.1)

 30-day in-hospital mortality

33 (6.7)

Readmission for any pneumococcal infection

 Within 30 days from discharge date

1 (0.2)

 Anytime during study period

6 (1.2)

  1. SD standard deviation, PCV13 13-valent pneumococcal conjugate vaccination, PPSV23 23-valent pneumococcal polysaccharide vaccine, IQR inter-quartile range, ICU intensive care unit